Published in Bioorg Med Chem on October 13, 2014
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1990) 2.53
Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet (2003) 2.23
Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. Antimicrob Agents Chemother (2002) 1.79
HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res (2008) 1.70
Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem (1987) 1.66
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 1.59
Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res (2008) 1.56
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
Antiviral drugs: current state of the art. J Clin Virol (2001) 1.31
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther (2002) 1.19
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS (2003) 1.17
Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.14
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci (2000) 1.08
Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates. Int J Biochem Cell Biol (2004) 1.01
Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des (2004) 0.98
Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. Bioorg Med Chem (2005) 0.97
Comparative Quantitative Structureminus signActivity Relationship Studies on Anti-HIV Drugs. Chem Rev (1999) 0.96
Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2',3'-dideoxy-3'-thiacytidine. J Med Chem (2012) 0.95
Emtricitabine prodrugs with improved anti-HIV activity and cellular uptake. Mol Pharm (2012) 0.92
Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr (2004) 0.92
Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother (2003) 0.84
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs. J Med Chem (2007) 0.80
Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. Tetrahedron (2011) 0.79
Current insights into reverse transcriptase inhibitor-associated resistance. Antivir Ther (2001) 0.77
Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses. ACS Med Chem Lett (2013) 0.77
Interpretation of resistance assay results. Antivir Ther (2001) 0.77
Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res (2013) 0.90